The influence of marrow cell dose on the outcome of allogeneic bone marrow transplantation (BMT) has been debated. The aim of this study was to evaluate the impact of grafted cell dose on graft function, graft-versus-host disease (GvHD) and transplantrelated mortality (TRM). We report 851 consecutive patients grafted between 1976 and 1999 who received unmanipulated bone marrow. Median follow up for deceased patients was 120 days (range 1-6533) and 2412 days (range 180-8842) for surviving patients. The donor type was an HLA identical sibling (n=701), a mismatched related donor (n=33) or a matched unrelated donor (n=117). Median recipient age at transplant was 29 years (range 1-66). The disease was in early phase in 61% (n=518) of the patients. The conditioning regimen was cyclophosphamide (CY) alone (n=92) , CY-total body irradiation (n=616), CY-thiotepa (n=109), or other combinations (n=34). Acute GvHD prophylaxis consisted of cyclosporin A with or without methotrexate. Median number of nucleated cells infused was 3.3x108/Kg (25°percentile 2.3x108/Kg , 75°percentile 4.8x108/Kg). Patients were stratified in three groups according to low, intermediate or high cell dose: Ͻ= 2.3 (n=207), Ͻ= 4.8 (n=435), Ͼ 4.8x108/Kg nucleated cells (n=209). Patients receiving Ͼ4.8x108/kg cells had significantly higher platelets counts on days +20, +50, +100, +180, +365. The same patients also had less acute GvHD grade II or more (p=0.02). The actuarial 10 year transplant-related mortality was 45% vs 36% vs 29% (p=0.001) in patients receiving low, intermediate or a high marrow cell dose. The actuarial 10 year survival was significantly different in the three groups of patients: 42% vs 47% vs 56% respectively (p=0.004). In multivariate analysis on TRM, with patient and transplant variables, cell dose was the most significant predictor (p=0.00001) together with donor type (p=0.004), patients age (p=0.001) and conditioning regimen (p=0.02). The cell dose effect was not linear: it was most significant in 751 patients receiving Ͻ=6x10ˆ8/kg cells (p=0.002) and it is not significant in 94 patients receiving Ͼ6x10ˆ8/kg cells (p=0.2). In conclusion cell dose influences significantly marrow function and transplant related mortality and we would recommend using at least 4x10ˆ8/kg marrow cells. Whether this applies to both marrow and peripheral blood transplants, remains to be determined. Stem cell transplants from family members sharing one HLA-haplotype and differing in 0 -3 HLA-antigens (A, B, DR) of the second haplotype carry a high risk of rejection and graft-versus-host disease. Pretransplant conditioning consisted of total body irradiation with 12 Gy, a donor buffy coat transfusion, antithymocyte globulin and cyclophosphamide. Post-transplant cyclosporine A and methotrexate was given routinely for prevention of graft-versus-host disease (GvHD). We have studied the use of CD6-negative blood stem cells 6 days after marrow transplantation for facilitating engraftment of haploidentical marrow trans-plants. Peripheral blood stem cells (PBSC) depleted of CD6-positive T-cells by immunomag-netic bead depletion suppressed the mixed leukocyte culture between HLA-mismatched indi-viduals. Suppression was exhibited by the CD8-positive subset of CD6-negative cells and suppression was abrogated by the depletion of CD8-positive cells and not by the depletion of NK-cells or monocytes. 21 patients were grafted with marrow and CD6-negative PBSC for advanced leukemia (refractory AML 12 patients, refractory ALL 4 pats., refractory CLL 2 pts., MDS 1 pt., advanced CML 1pt., refractory NHL 1pt.). HLA-antigen differences of the donor (host-versus-graft direction) involved 3 antigens in 2, 2 antigens in 6, one antigen in 8 and no antigen in 2 pts. In the GVH direction 3 antigens were involved in one, 2 antigens in 5, one antigen in 8 pts. and no antigen in 4 pts. 11 patients were male and 10 female, the median age was 39 years (range 17 -53). Three pts. died early and were excluded from further evaluation. 18 pts. showed full engraftment. GvHD was mild in 12 pts. given CD6-negative PBSC and severe in a pt. given CD34-positive PBSC on day 6. The 2 year actuarial survival is 22 %, the relapse rate 60 % and the transplant-related mortality 38 %. Causes of deaths were recurrent leukemia in 7 pts., viral infections in 4 pts. and mycoplasma infection in 1 pt. We conclude from our study that CD6-negative, CD8-positive cells facilitate engraftment of HLA-haploidentical stem cell transplants in pts. with very advanced leukemia. However in-fections present therapeutic problems. Future attempts will be directed to transplantation at an earlier stage of the disease and better prevention of infections by improving immune reconstitution. The use of CD34+ stem cells prevents graft-versus-host disease even after haplo-identical transplantation. However, in some patients delayed T-cell recovery may lead to severe viral infections. Donor lymphocyte infusions could prevent viral infections but are restricted to very small amounts due to the risk of graft-versus-host disease. DLI could be used safely after selective depletion of alloreactive T-cells. We therefore established a system to generate specifically activated T-cells and their immunomagnetic depletion using antibodies against the activation markers CD25, CD69 and HLA-DR. Alloreactive T-cells were generated in a mixed lymphocyte culture with irradiated recipient a) mononuclear cells, b) MNC after overnight incubation with IFNg and TNFa or c) dendritic cells. After 72 h cells were positive for CD25 a) 4.7%, b) 7.8% or c) 7.5%, CD69 a)2.1, b)1.7 or c)8.6 and HLA-DR a)20.4, b)28.8 or c)52.3. Thymidine uptake was higher by using dendritic cells (69fold) or lymphocytes after overnight incubation with IFNg and TNFa (1,9fold) than using non-manipulated lymphocytes for stimulation. After immuno-magnetic depletion with CD25, CD69 and HLA-DR activation marker were minimized to a) 0.1 % b) S57
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Generation, identification and depletion of allo-reactive T-cells for adoptive immunotherapy after haploidentical transplantation E. Rettinger, M. Schumm, P. Lang, J. Greil, M. Pfeiffer, R. Handgretinger, D. Niethammer (Tuebingen, D)
The use of CD34+ stem cells prevents graft-versus-host disease even after haplo-identical transplantation. However, in some patients delayed T-cell recovery may lead to severe viral infections. Donor lymphocyte infusions could prevent viral infections but are restricted to very small amounts due to the risk of graft-versus-host disease. DLI could be used safely after selective depletion of alloreactive T-cells. We therefore established a system to generate specifically activated T-cells and their immunomagnetic depletion using antibodies against the activation markers CD25, CD69 and HLA-DR. Alloreactive T-cells were generated in a mixed lymphocyte culture with irradiated recipient a) mononuclear cells, b) MNC after overnight incubation with IFNg and TNFa or c) dendritic cells. After 72 h cells were positive for CD25 a) 4.7%, b) 7.8% or c) 7.5%, CD69 a)2.1, b)1.7 or c)8.6 and HLA-DR a)20.4, b)28.8 or c)52.3. Thymidine uptake was higher by using dendritic cells (69fold) or lymphocytes after overnight incubation with IFNg and TNFa (1,9fold) than using non-manipulated lymphocytes for stimulation. After immuno-magnetic depletion with CD25, CD69 and HLA-DR activation marker were minimized to a) 0.1 % b) 0.08% and c) 1.1 % of positive cells determined with secondary GAM-antibody. Thymidine uptake after secondary coculture with irradiated stimulator cells was still strongly reduced after 5 days in group c) (97.1% reduction), while little or no reduction was seen in a) (5%) and b) (none). Reactivity of T-cells after depletion against third party or tetanus toxoid was reduced between 0 and 81 percent. Depletion of allo-reactive cells could also be confirmed in an IFNg-ELISPOT assay. Further FACS analysis showed that depletion using only CD25 and CD69 was less successful and that the expression of other activation markers like CD71, CD95 and CD161 was also reduced after depletion (CD71: 75% , CD95: 41% and CD161: 58%).
In conclusion, non-alloreactive T-cells can be generated in mixed lymphocyte culture and subsequent depletion of allo-reactive cells. Strong activation of T-cells before depletion correlated to a strong reduction of allo-reactivity afterwards, obviously linked to the higher expression of activation markers. Depletion of activated T-cells after coculture with stimulator cells is a feasible way to generate a large number of non-alloreactive T-cells and enables adoptive immunotherapy after haplo-identical transplantation.
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Factors predicting CD34 yields above 2x10ˆ6/kg with growth factor mobilization S. Kulkarni, R. Powles, D. Cunningham, B. Cheung, B. Sirohi, R. Saso, J. Treleaven (Sutton, UK) 502 patients (Median age:47yr., M:304, F:198, Ac.Leukaemia=86, Myeloma=202, NHL=128, HD=86) who received growth factor priming and had CD34 estimation on two consecutive harvests were analysed. The main aim was to identify predictors of failure to mobilize adequate CD34 cells (less than 2x10ˆ6/Kg) in two consecutive harvests. The median body weight was 75kg.(range:40-124). 424/502 patients received G-CSF in the dose of 12-16micg/kg/day for 4 days and PBSC were collected on day 4 and 5. Seventy-eight patients received lower dose G-CSF(6-11micg/kg/day for 4days) as apart of randomised trial. The median number of chemotherapy cycles before harvest was 6 (range:0-37) and the median number of chemotherapy lines was 1 (range:1-7, median interval from last chemo:62d.). 44 patients had received autograft before the current harvest (Ac.Leuk.=3, MM=26, NHL=10, HD=5; p=0.04). 107/502 also received local radiotherapy in the past (Ac.Leuk=5, MM=33, NHL=27, HD=42, p=0.001). The median total CD34 yield for the whole group was 1.92x10ˆ6/kg (range:0-112) and there were no differences in 4 disease types (Ac.Leuk=2.19, MM=1.8, NHL=2.04, HD=1.96; p=0.4). Univariate analysis was performed to identify the influence of age, sex, weight, haematological parameters prior to start of G-CSF and previous therapy on the risk of failed harvest. In univariate analysis, age Ͼ45 (p=0.0001), advanced stage (p=0.0002) , WBCϽ 5 (p=0.0007), platelet Ͻ 250 (pϽ0.0001) monocytesϽ 1 (p=0.035), Ͼ6 cycles of chemo (pϽ0.0001), Ͼ1 line of chemo (pϽ0.0001) and previous autograft (p=0.009) were associated with increased risk. In multi-variate analysis WBC (RR: 1.63, 95%CI:1.2-2.3, p=0.002), platelet count (RR:1.63, 95%CI:1.2-2.3, p=0.002), previous autograft (RR:1.84, 95% CI:1.2-2.9,p=0.006) and Ͼ6 prior chemo cycles (RR:1.64, 95%CI:1.2-2.2, p=0.002) were independent predictors. 455/502 patients had values available for all risk factors (RF) and they were divided into 3 groups with 0 RF (n=61), 1-2RF (n=289) and 3-4 RF (n=105). The probability of failed harvest in these groups was 32%, 46% and 70% respectively (p=0.0001). In conclusion, this single center analysis identifies predictors of failed mobilization. As most of them are modiafiable it may be possible to use this risk stratification to time the harvest procedure and reduce the incidence of failed mobilization with associated cost saving. Objective: The aim of this study was to analyse the toxicity and survival of allogeneic SCT in patients older than 50, and compare the results with those obtained in a young-adult cohort (20-40 years). Patients: From I-90 to III-2000, 32 patients *50 years (old population) and 97 between 20-40 years (young population) received an allo-SCT from an identical sibling donor. Data for the old and young population were respectively: Median age 52.5 years (50-59) and 32 (20-40) P .0001; Underlying disease (CML 16 /50; myelodisplastic syndrome 7/6, AML 6/41, other diagnosis 3/0); High risk patients (CML in accelerated phase or blast crisis, MDS with *6% blast in marrow, second transplants, refractory leukemia or with active disease) were more frequent in the old group (41% vs. 23% P .06). Median follow up was 2 and 4 years respectively, P .004. The majority of the SCTs in both groups were performed with bone marrow (95%), conditioned with busulfan+ cyclophosphamide (80%) and received cyclosporine+methotrexate as GVHD prophylaxis. Grafts were non-T depleted. Results: We observed a low incidence of acute toxicities in the old group without significant differences compare with the young group: (old vs. young population) liver veno-occlusive disease (VOD) 9% vs. 19.6%; Acute GVHD (II-IV) 22% vs. 32.6%; early (Ͻ100 days) transplant-related mortality (TRM) 9% vs. 14.4%. There were also no difference in chronic GVHD (65% vs. 52.5%) and relapse incidence (22% vs. 15.4%). The Kaplan-Meier survival at 2 years were (old vs. young group): 59.6% vs. 61.4% for the whole groups; 85.2% vs. 66.8% in CML; 23.1% vs. 53.1% in SMD+LAM, P .03; 76% vs. 67% in standard risk patients and 36% vs. 42% in high risk. In the group of SMD+LAM there were a trend to more high-risk patients in the old group (61.5% vs. 31.9% P .06). Cox analyses in this subgroup of patients showed a worse survival for high-risk patients (hazard ratio 2, P .05) but not for old patients (HR 1.8, P .11). Conclusions. In our experience, allogeneic SCT from HLA-identical related donors in patients older than 50 years was associated with a low incidence of transplant-related complications (VOD, GVHD, TRM), not significantly different from the incidence in younger adult population. Survival is probably more related to the prognosis of the underlining disease than with the age of the patient. Patients with 50-59 years old should not be excluded for a conventional allogeneic SCT based on age alone. To maximize GVL effects while minimizing the risk of GVHD, we undertook a study of allogeneic CD34-selected PBSC transplantation followed by CD8-depleted DLI (study group) in 21 pts with hematological malignancies. PBSC were collected in matched (N=14) or one-MM (N=7) related donors and CD34-selected using the Isolex 300i. GVHD prophylaxis was carried out with CSP with (N=6) or without (N=15) MTX. On day 60 post-PBSCT, donors lymphocytes were collected, CD8-depleted and separated into 3 aliquots of 2x106, 1x107 and 5x107 CD3+ cells/kg, respectively (patients 1-13) or into 2 aliquots of 1x107 and 5x107 CD3+ cells/kg (patients 14-21). The 1st aliquot was infused on day 60 and the other 1 (2) cryopreserved and infused on days 100 (and 140). Results were compared with an historical group of 21pts receiving unmanipulated marrow (BMT group) matched for age, sex and diagnosis. 13/21 pts in the study group versus 10/21pts in the BMT group were high risk transplants. 4 pts in the study group died before receiving DLI (MOF:2, VOD:1, leukemia:1). 1pt developed severe respiratory failure and did not receive DLI. She is still alive in CR at day 150. The other 16 pts were in CR on day 60 and received the first DLI. 2 ALL pts relapsed between days 60 and 100 and received the pooled 2nd and 3rd aliquots: 1achieved a CR with chemotherapy and DLI but relapsed later and died and the other died of leukemia on day 100. In addition, 1pt died suddenly at home of unknown reason in CCR. The other 13 received the scheduled 2nd (and 3rd ) DLI and 11 remain in CR 101-1137 (median 452) days post-HSCT. 2 ALL pts developed local (thymic and CNS) relapses on days 315 and 135 and were reinduced into CR with chemo-and radio-therapy. Acute GVHD grade I occurred in 4 pts and grade II also in 4. Limited chronic GVHD occurred in 2 pts, both older pts with a female donor and 1 HLA MM Finally, 1 pt developed grade II acute GVHD after DLI. Pts in the study group had significantly faster neutrophil (11 vs 21 days to 0.5x109/L, pϽ0.0001) and platelet (16 vs 24 days to 20x109/L, p=0.039) recovery and were discharged earlier than BMT pts (21 vs 35 days, p=0.029). The actuarial incidence of grade II-IV acute GVHD was 19% for the study group versus 77% for the BMT group (pϽ0.001). The actuarial 2-yr probability of chronic GVHD was 22% in the study group versus 72% in the BMT group (p=0.011). There was no difference in relapse rate (37% vs 35%) or overall survival (53% vs 52%). We conclude that allogeneic CD34-selected PBSCT followed by pre-emptive CD8-depleted DLI appears to be an effective strategy to separate the GVL effect from GVHD.
